Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2015-03-09 Share Issue/Capital Cha…
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Information relative au nombre total de droits de vote et au nombre d'actions composant le capital social
Share Issue/Capital Change Classification · 95% confidence The document is titled "Information relative au nombre total de droits de vote et au nombre d'actions composant le capital social" (Information relating to the total number of voting rights and the number of shares comprising the share capital) as of March 9, 2015. It explicitly states it is published in accordance with Article 223-16 of the General Regulation of the AMF (Autorité des marchés financiers). This type of mandatory disclosure, detailing the total share count and voting rights, is a specific regulatory filing requirement, often related to capital structure updates or pre-AGM/EGM disclosures. Since it is a direct regulatory disclosure about the capital structure (number of shares and voting rights) and not a general announcement of a report (RPA) or a change in major shareholding (MRQ), it fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Share Capital/Voting Rights Disclosure'. However, given the content directly relates to the capital structure, it is closely related to 'Share Issue/Capital Change' (SHA), but SHA is usually for the *action* of issuing/changing, whereas this is a periodic *report* on the existing structure. Given the options, RNS is the most appropriate fallback for a specific regulatory disclosure not covered elsewhere, although it is a very specific type of capital information.
2015-03-09 French
Disclosure of the total number of voting rights and the number of shares of the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is titled 'Disclosure of the total number of voting rights and the number of shares of the share capital' and explicitly states the number of shares and voting rights as of March 9th, 2015, referencing regulatory articles (article 223-16). This type of mandatory disclosure regarding the capital structure and voting power directly relates to shareholder rights and the composition of the share base. Among the provided codes, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is the most specific fit for a disclosure detailing the total number of voting rights and shares, which is a key component of general meeting governance and shareholder information.
2015-03-09 English
Quantum Genomics reports total capital increase after stabilization period: EUR 12.9 million
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the final results of a capital increase, specifically noting that the overallotment option was fully exercised, raising a total of €12.9 million through the issuance of new shares. This directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA).
2015-02-25 English
Apport complémentaire au contrat de liquidité
Capital/Financing Update Classification · 95% confidence The document is a press release dated February 24, 2015, titled "Apport complémentaire au contrat de liquidité" (Complementary contribution to the liquidity contract). It explicitly details a cash contribution (€250,000) made to the company's liquidity contract managed by Aurel BGC, and also reports the existing balance as of December 31, 2014. This action—managing the liquidity contract, which involves buying/selling shares or adding funds to maintain market presence—is directly related to the company's own share transactions or capital management activities. Since the document describes an action taken regarding the liquidity contract (which often involves share transactions or capital maintenance), it fits best under 'Transaction in Own Shares' (POS) or potentially 'Capital/Financing Update' (CAP). Given the context of a liquidity contract, which is a mechanism often involving share repurchases or maintenance of market making, POS is the most specific fit for actions related to the company's own stock management outside of a formal share issue/buyback program announcement. It is not a general financing update (CAP) but a specific operational update on share/liquidity management. It is too specific for RNS and does not match any other category.
2015-02-24 French
Montant définitif de l'augmentation de capital de Quantum Genomics à l'issue des opérations de stabilisation : 12,9 M EUR
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the final amount raised (€12.9 M) from a capital increase, specifically noting the full exercise of the over-allotment option (Greenshoe) and the resulting number of shares and market capitalization. This directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it contains the substantive financial outcome of the capital operation.
2015-02-24 French
Remarkable uptake in Quantum Genomics IPO* : EUR 11.2 million raised
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the successful completion of an Initial Public Offering (IPO) for Quantum Genomics, detailing the amount raised (€11.2 million), oversubscription rates, the final share price (€6.30), and the intended use of funds (financing Phase IIa clinical trials). This event involves raising capital through the issuance of new shares, which directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full Annual Report (10-K), an Earnings Release (ER), or a Dividend Notice (DIV). Since it is a detailed announcement about the financing transaction itself, it is classified as CAP rather than a general Regulatory Filing (RNS).
2015-02-17 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.